Shares of Vascular Biogenics VBLT were flat in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 25.00% over the past year to ($0.15), which beat the estimate of ($0.17).
Revenue of $366,000 rose by 67.12% year over year, which beat the estimate of $160,000.
Outlook
Vascular Biogenics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: May 14, 2020
Time: 10:02 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/ubiyng5a
Technicals
52-week high: $1.64
52-week low: $0.90
Price action over last quarter: Up 15.07%
Company Profile
Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.